Benzinga | Apr 6, 2021 06:50AM EDT

Jefferies Downgrades ACADIA Pharmaceuticals to Hold, Lowers Price Target to $21

Jefferies analyst Chris Howerton downgrades ACADIA Pharmaceuticals (NASDAQ:ACAD) from Buy to Hold and lowers the price target from $40 to $21.